GenEvolutioN is an innovative and privately owned GLP-certified contract research organization (CRO) with many years of in vitro toxicology expertise and specialist knowledge in cell-based methods. In a short time, the company has established itself as a supplier of high-tech and advanced testing services with customers in the pharmaceutical, cosmetics and chemical industries in seven countries.
"GenEvolutioN possesses an impressive level of expertise in the field of alternative testing without animal models and gives us access to world-leading customers within our prioritized industries. Collaboration with strong partners is part of our commercial strategy and together with GenEvolutioN, we continue to establish the GARD™ technology in the important European market," says Axel Sjöblad, CEO of
"GenEvolutioN stands for quality and scientific excellence. We offer only the best services and tools in line with the evolution of biological and technological progress; therefore, we are very careful with partnerships and the services we add to our portfolio. Our customers are increasingly demanding sensitization testing and it is gratifying that we now can offer them the high-performance GARD™ technology," says
The agreement gives GenEvolutioN the right to market and sell
The agreement between
For more information, please contact:
Axel Sjöblad, CEO,
Email: axel.sjoblad@senzagen.com | Mobil: +46 705-35 93 51
Email: francis.finot@genevolution.fr | Mobil: +33 (0)- 65 75 94 78
About GARD™
GARD™ consists of a group of tests for analyzing chemicals' ability to start an allergic reaction in humans. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence. By analyzing hundreds of markers, GARD™ generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today's standard method - tests on animals - which only achieves 70-75 percent accuracy. The product portfolio consists of tests for skin and respiratory allergy: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.
About
About GenEvolutioN
GenEvolutioN established in 2017, is an expert spin off, dedicated to in vitro genetic toxicology and toxicology expertise using new Human cell models. GenEvolutioN is in line with the evolution of biological and technological progress. Please visit www.genevolution.fr.
https://news.cision.com/senzagen/r/senzagen-signs-distribution-agreement-with-genevolution-in-france,c2992667
https://mb.cision.com/Main/14439/2992667/1163057.pdf
https://news.cision.com/senzagen/i/senzagen-logo,c2729315
(c) 2019 Cision. All rights reserved., source